Delhi High Court asks Roche to explain lawsuit over Avastin copy
NEW DELHI: The Delhi High Court has once again asked Swiss biotech drug giant Roche to explain why it is suing the Drug Controller General of India (DCGI) and Hyderabad-based Hetero Drugs over the approval process for a biosimilar or copy of complex biotech cancer drug bevacizumab. Roche, which invented the drug and markets it under the blockbuster brand 'Avastin', has argued that Hetero's drug is not a biosimilar to bevacizumab and therefore can't use the name to market itself here...